|
|
Article: Ludwig Institute for Cancer Research and PowderMed Initiate A Phase I Clinical Trial for a Novel Therapeutic Cancer Vaccine; Phase I Clinical Trial of Therapeutic Cancer Vaccine Commences in New York, in Patients With Non-small Cell Lung Cancer (NSCLC), Using PowderMed's Novel DNA-on-Gold Technology.
- Article from:
- PR Newswire
- Article date:
- September 17, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
OXFORD, England, September 17 /PRNewswire/ -- PowderMed Ltd (PowderMed), a company focusing on the development of therapeutic DNA vaccines, in collaboration with its partner, the Ludwig Institute for Cancer Research (LICR), have announced that they have initiated a Phase I trial of a novel therapeutic DNA cancer vaccine that uses DNA encoding for the NY-ESO-1 tumour specific antigen and the Particle Mediated Epidermal Delivery (PMED(TM)) technology owned by PowderMed.
The trial, being carried out at the Weill Medical College of Cornell University in New York, will be conducted in patients with non-small cell lung cancer (NSCLC) and will recruit up to 18 patients ...